Medical Doctor Program year 2023 Reported 2019–2023 Source: CMS Open Payments, 2026 publication

Satnam Mahal

Psychiatry Osage Beach, MO Medical Doctor

NPI 1053399915 CMS profile 319798

1197 Highway Kk, Osage Beach, MO 65065

Open in the dashboard

General payments

$3,139

227 records reported · program years 2019–2023

Research payments

$0

Paid to them · None reported · program years 2019–2023

Ownership & investment interest

$0

None reported

Through program year 2023, Satnam Mahal of Osage Beach, MO is reported in the CMS Open Payments database as having received $3,139 across 227 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 84th percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $206 12
2022 General $1,168 68
2021 General $401 24
2020 General $320 20
2019 General $1,043 103

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Satnam Mahal
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to Satnam Mahal were reported at $0. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year Satnam Mahal Psychiatry median Middle half National median
2019 $1,043 $184 $59–$605 $163
2020 $320 $119 $36–$372 $114
2021 $401 $143 $43–$576 $132
2022 $1,168 $153 $50–$590 $149
2023 $206 $170 $56–$651 $160
2024 $0 $179 $57–$673 $164
2025 $0 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2019–2023
  1. Otsuka America Pharmaceutical, Inc. $521 44 payments
  2. Janssen Pharmaceuticals, Inc $426 35 payments
  3. Alkermes, Inc. $337 23 payments
  4. AbbVie, Inc. $306 17 payments
  5. Neurocrine Biosciences, Inc. $279 18 payments
  6. Teva Pharmaceuticals USA, Inc. $250 12 payments
  7. Allergan Inc. $193 21 payments
  8. Indivior Inc. $179 10 payments
  9. ITI, Inc. $116 8 payments
  10. Avanir Pharmaceuticals, Inc. $100 6 payments
  11. Other $432 33 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2023
  1. Food and Beverage $3,122 222 payments
  2. Education $17 5 payments
Products named General payments · program years 2019–2023
  1. ABILIFY MAINTENA $353 33 payments
  2. VRAYLAR $306 17 payments
  3. ARISTADA INITIO $284 20 payments
  4. ARISTADA Cns $284 20 payments
  5. ARISTADA Cns $284 20 payments
  6. INVEGA SUSTENNA $261 16 payments
  7. AUSTEDO $250 12 payments
  8. SPRAVATO $240 24 payments
  9. REXULTI $204 14 payments
  10. ARISTADA Cns $201 14 payments
  11. Other $2,033 142 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 63 drugs

Part D claims

5,526

Median for Psychiatry: 574

Drug cost

$715,091

Median for Psychiatry: $27,624

Branded share of claims

18.2%

Median for Psychiatry: 17%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Austedo Deutetrabenazine Brand 31 $206,813
Abilify Maintena Aripiprazole Brand 48 $128,315
Invega Sustenna Paliperidone Palmitate Brand 36 $123,071
Rexulti Brexpiprazole Brand 71 $93,613
Vraylar Cariprazine Hcl Brand 20 $35,482
Seroquel Xr Quetiapine Fumarate Brand 24 $13,584
Trintellix Vortioxetine Hydrobromide Brand 21 $11,708
Aripiprazole Generic 295 $10,146
Lurasidone Hcl Generic 66 $7,369
Atomoxetine Hcl Generic 49 $5,640

The 10 drugs with the highest cost, of 63 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 20,488 Part D prescribers listed as Psychiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 3 billing codes

Paid by Medicare

$12,262

Medicare's payments for the services billed

Medicare patients

77

Average age 60

Services billed

224

47 women, 30 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Depression 64%
High blood pressure 61%
Arthritis 30%
Diabetes 23%
COPD 21%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

227 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in Missouri

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record